2-氯嘧啶并[2,1-a]异喹啉-4-酮 | 42398-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 中文名称: 2-氯嘧啶并[2,1-a]异喹啉-4-酮
• 英文名称: 2-chloropyrimido[2,1-a]isoquinoline-4-one
• 英文别名: 2-chloro-4H-pyrimido<2,1-a>isoquinolin-4-one；2-Chlor-pyrimido-<2,1-a>-isochinolin-4-on；2-Chloropyrimido[2,1-a]isoquinolin-4-one
• CAS: 42398-55-0
• 化学式: C₁₂H₇ClN₂O
• 分子量: 230.653
• InChiKey: BYRWJYALSBHOFU-UHFFFAOYSA-N

物化性质

• 熔点：
  197-199 °C
• 沸点：
  359.8±52.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-氯嘧啶并[2,1-a]异喹啉-4-酮 在 NaCO₃ 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 2-(4-ethyl-1-piperazinyl)-4H-pyrimido<2,1-a>isoquinolin-4-one
  参考文献：
  名称：

  1,2-Fused pyrimidines VII. 3-(Dialkylamino)-1H-pyrimido[1,2-a]quinolin-1-ones and 2-(dialkylamino)-4H-pyrimido[2,1-a]isoquinolin-4-ones as antiplatelet compounds

  摘要：

  A number of 3-(dialkylamino)-1H-pyrimido[1,2-a]quinolin-1 ones 3 and 2-(dialkylamino)-4H-pyrimido [2,1-a]isoquinolin-4-ones 4 were prepared by treating the corresponding chloro derivatives with an excess of dialkylamines. The highest in vitro antiplatelet activity was obtained when the dialkylamino substituent was 1-piperazinyl (compounds 3g and 4e). The novel 2-(1-piperazinyl)-4H-pyrido[ ,2-a]pyrimidin-4-one 2a was also prepared by an analogous procedure, which resulted in the most active compound towards all the platelet aggregation inducers used (ADP, collagen, A 23187). Moreover, some examples of 1-(dialkylamino)-3H pyrimido[l,2-a]quinolin-3-ones 5 and 4-(dialkylamino)-2H-pyrimido[2,1-a]isoquinolin-2-ones 6 were also obtained (together with negligible or lower amounts of the corresponding isomers 3 and 4, respectively) from the cyclocondensation of the appropriate ethyl N,N-dialkylmalonamate/phosphorus oxychloride reagents 13 with 2-aminoquinoline or 1-aminoisoquinoline. These;latter compounds showed a rather low antiplatelet activity.

  DOI：

  10.1016/0223-5234(96)88206-7
• 作为产物：
  描述：

  1-氨基异喹啉 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 9.0h， 生成 2-氯嘧啶并[2,1-a]异喹啉-4-酮
  参考文献：
  名称：

  DNA依赖性蛋白激酶的选择性苯并吡喃酮和嘧啶[2,1-a]异喹啉-4-酮抑制剂：合成，结构活性研究和体外人类肿瘤细胞系的放射增敏作用。

  摘要：

  合成了各种各样的chromen-2-one，chromen-4-one和pyrimidoisoquinolin-4-one衍生物，并评估了其对DNA修复酶DNA依赖性蛋白激酶（DNA-PK）的抑制活性，目的是阐明效价和激酶选择性的构效关系。DNA-PK抑制活性在评估的一系列化合物（IC（50）值范围从0.19到> 10 microM）上有很大差异，其中7,8-苯并铬基-4-酮和嘧啶基[2,1]表现出优异的活性。 -a] isoquinolin-4-one模板。相比之下，基于苯并色素-2-酮（香豆素）或2-芳基-7,8-苯并色素-4-酮（黄酮）支架的抑制剂效力较低。至关重要的是，这些研究揭示了在苯并吡喃酮和嘧啶基2位上的结构活性关系非常受约束[2，1-a]异喹啉-4-酮药效基团，在此位置仅可耐受2-吗啉代或2-（2'-甲基吗啉代）基团。用最有效的抑制剂NU7163（48; IC（50）= 0

  DOI：

  10.1021/jm049526a

文献信息

• Dna-pk inhibitors
  申请人：——

  公开号：US20040192687A1

  公开（公告）日：2004-09-30

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R 1 and R 2 are independently hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR 4 and O, O and CR′ 4 and NR″ 4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R 3 and R 4 or R′ 4 is an optionally substituted C 3-20 heteroaryl or C 5-20 aryl group, and the other of R 3 and R 4 or R′ 4 is H, or R 3 and R 4 or R″ 4 together are —A—B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM. 1

  本发明涉及使用式(I)化合物及其异构体、盐、溶剂合物、化学保护形式及其前药，在制备抑制DNA-PK活性的药物方面使用。其中，R1和R2分别为氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基，或者与它们连接的氮原子一起形成含有4到8个环原子的可选取代杂环环；X和Y从CR4和O、O和CR'4以及NR"4和N中选择，其中不饱和度在环中适当位置，且R3和R4或R'4中的一个为可选取代的C3-20杂芳基或C5-20芳基，而另一个为氢，或者R3和R4或R"4一起为-A-B-，它们共同表示一个融合的可选取代芳香环。这些化合物与PI 3-激酶和/或ATM相比，也具有选择性抑制DNA-PK活性的作用。
• DNA-PK INHIBITORS
  申请人：Martin Morrison Barr Niall

  公开号：US20070238729A1

  公开（公告）日：2007-10-11

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R 1 and R 2 are independently hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR 4 and O, O and CR′ 4 and NR″ 4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R 3 and R 4 or R′ 4 is an optionally substituted C 3-20 heteroaryl or C 5-20 aryl group, and the other of R 3 and R 4 or R′ 4 is H, or R 3 and R 4 or R″ 4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.

  本发明涉及使用式(I)的化合物及其异构体、盐、溶剂合物、化学保护形式和前药，在制备抑制DNA-PK活性的药物方面有用。其中，R1和R2独立地表示氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基，或者与它们连接的氮原子一起形成可选取代的含有4到8个环原子的杂环环；X和Y选自CR4和O，O和CR'4以及NR"4和N，其中不饱和度在环中适当位置，其中R3和R4或R'4中的一个为可选取代的C3-20杂芳基或C5-20芳基，而另一个为H，或者R3和R4或R"4在一起为-A-B-，代表一种融合的可选取代芳香环。这些化合物与PI 3-激酶和/或ATM相比，具有选择性地抑制DNA-PK的活性。
• US7226918B2
  申请人：——

  公开号：US7226918B2

  公开（公告）日：2007-06-05
• US7674823B2
  申请人：——

  公开号：US7674823B2

  公开（公告）日：2010-03-09
• [EN] INHIBITORS OF MTOR AND METHODS OF TREATMENT USING SAME<br/>[FR] INHIBITEURS DE MTOR ET METHODES DE TRAITEMENT METTANT EN OEVRE CES INHIBITEURS
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2008148074A2

  公开（公告）日：2008-12-04

  [EN] The present invention provides novel compounds that inhibit mTOR activity. Compositions, including pharmaceutical compositions, comprising compounds of the present invention are also provided. The present invention also provides methods of treatment comprising administering compositions of the present invention to a subject in need thereof.
  [FR] L'invention concerne de nouveaux composés inhibant l'activité de mTOR. L'invention concerne également des compositions, notamment des compositions pharmaceutiques, contenant ces composés. L'invention concerne encore des méthodes de traitement consistant à administrer ces compositions à un patient nécessitant un tel traitement.